Related Experiment Videos
Interferon-A 2a administration in chronic anergic brucellosis
P Boura1, G Tsapas, J Kountouras
12nd Medical Clinic, Aristotelian University of Thessaloniki, Greece.
Hepato-Gastroenterology
|November 1, 1995
Summary
Interferon-alpha 2a (IFN) successfully treated chronic anergic brucellosis in two patients. This immunotherapy restored immune function, leading to disease remission and improved inflammatory responses against brucella infection.
Area of Science:
- Immunology
- Infectious Diseases
- Pharmacology
Background:
- Chronic anergic brucellosis presents challenges with relapses and poor response to standard treatments.
- Patients often exhibit immunodeficiency and anergy to brucella antigens.
Observation:
- Two patients with chronic anergic brucellosis received a six-month treatment course of Interferon-alpha 2a (IFN).
- Treatment involved a loading dose followed by a maintenance regimen of subcutaneous IFN injections.
Findings:
- IFN administration led to clinical remission by the fourth month of treatment.
- Immunological markers improved, including decreased Coombs' agglutination titers, restored leucocyte migration index, normalized skin tests, and enhanced monocyte macrophage function.
- Immune responses against brucella antigens were restored.
Implications:
- Interferon-alpha 2a shows promise as a beneficial therapeutic agent for chronic anergic brucellosis.
- IFN treatment can restore defective immune responses, facilitating an effective inflammatory reaction against brucella infection.
- This approach may offer a new strategy for managing refractory cases of brucellosis.